IntelGenx Corp. Comments on CPI-300 Patent Infringement Complaint
IntelGenx Corp. Comments on CPI-300 Patent Infringement Complaint
MarketWatch - 33 minutes ago
SAINT LAURENT, QUEBEC, Aug 21, 2009 (MARKETWIRE via COMTEX) -- IntelGenx Corp. ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which ...
- Login or register to post comments
- 67 reads
- Feed: Biovail News
- Original article